SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response

Detalles Bibliográficos
Autores principales: Verhoeven, Frank, Lepiller, Quentin, Hecquet, Sophie, Prati, Clément, Wendling, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de rhumatologie. Published by Elsevier Masson SAS. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411658/
https://www.ncbi.nlm.nih.gov/pubmed/34481943
http://dx.doi.org/10.1016/j.jbspin.2021.105258
_version_ 1783747338690363392
author Verhoeven, Frank
Lepiller, Quentin
Hecquet, Sophie
Prati, Clément
Wendling, Daniel
author_facet Verhoeven, Frank
Lepiller, Quentin
Hecquet, Sophie
Prati, Clément
Wendling, Daniel
author_sort Verhoeven, Frank
collection PubMed
description
format Online
Article
Text
id pubmed-8411658
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Société française de rhumatologie. Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-84116582021-09-03 SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response Verhoeven, Frank Lepiller, Quentin Hecquet, Sophie Prati, Clément Wendling, Daniel Joint Bone Spine Letter to the Editor Société française de rhumatologie. Published by Elsevier Masson SAS. 2021-12 2021-09-02 /pmc/articles/PMC8411658/ /pubmed/34481943 http://dx.doi.org/10.1016/j.jbspin.2021.105258 Text en © 2021 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Verhoeven, Frank
Lepiller, Quentin
Hecquet, Sophie
Prati, Clément
Wendling, Daniel
SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response
title SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response
title_full SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response
title_fullStr SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response
title_full_unstemmed SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response
title_short SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response
title_sort sars cov-2 vaccine and rituximab, timing might be a key for a better vaccine response
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411658/
https://www.ncbi.nlm.nih.gov/pubmed/34481943
http://dx.doi.org/10.1016/j.jbspin.2021.105258
work_keys_str_mv AT verhoevenfrank sarscov2vaccineandrituximabtimingmightbeakeyforabettervaccineresponse
AT lepillerquentin sarscov2vaccineandrituximabtimingmightbeakeyforabettervaccineresponse
AT hecquetsophie sarscov2vaccineandrituximabtimingmightbeakeyforabettervaccineresponse
AT praticlement sarscov2vaccineandrituximabtimingmightbeakeyforabettervaccineresponse
AT wendlingdaniel sarscov2vaccineandrituximabtimingmightbeakeyforabettervaccineresponse

Ejemplares similares